

PREVENIR 5 - Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting

Head : Amelineau Élisabeth, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 | Version : 2 | ID : 139

General

Identification

Detailed name Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting

Sign or acronym PREVENIR 5

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL N° 833542 version 12

General Aspects

Medical area Cardiology

Keywords Secondary prevention, care, persistence

Scientific investigator(s) (Contact)

Name of the director Amelineau

Surname Élisabeth

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone +33 (0)1 58 83 60 00

Email elisabeth.amelineau@bms.com

Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname Nathalie

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

Collaborations

Funding

Funding status	Private
----------------	---------

Details	Bristol-Myers Squibb France
---------	-----------------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb France (BMS)
---	-----------------------------------

Organisation status	Private
---------------------	---------

Additional contact

Main features

Type of database

Type of database	Study databases
------------------	-----------------

Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
---------------------------	--

Database recruitment is carried out by an intermediary	A selection of health institutions and services
--	---

Database recruitment is carried out as part of an interventional study	No
--	----

Additional information regarding sample selection.	random sampling in clusters
--	-----------------------------

Database objective

Main objective	Describe the persistence of secondary prevention therapeutics, between 3 and 30 months after hospitalization for a first acute coronary syndrome (ACS), in patients monitored by general practitioners
----------------	--

Inclusion criteria	Patient ≥ 18 years, outpatient seen in a general practice consultation, hospitalized in 2004 or 2005
--------------------	---

for a 1st ACS

Population type

Age
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered Sick population

Gender
Male
Woman

Geography area National

Detail of the geography area Metropolitan France

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2006

Date of last collection (YYYY or MM/YYYY) 2007

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 5111

Data

Database activity Data collection completed

Type of data collected
Clinical data
Biological data

Clinical data (detail) Direct physical measures

Biological data (detail) Total cholesterol, LDL chol, HDL chol, Triglycerides, fasting glucose

Presence of a biobank No

Health parameters studied Health care consumption and services

Care consumption (detail)

Medicines consumption

Procedures

Data collection method

Paper CRF

Participant monitoring

No

Links to administrative sources

No

Promotion and access

Promotion

Link to the document

[http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E\[Author\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E[Author])

Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only